| scholarly article | Q13442814 |
| P50 | author | Tadashi Kimura | Q87225863 |
| P2093 | author name string | Masaki Kobayashi | |
| Kenjiro Sawada | |||
| P2860 | cites work | The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. | Q53639283 |
| Ovarian cancer | Q54105461 | ||
| Embryonic mesodermal defects in alpha 5 integrin-deficient mice | Q71609560 | ||
| Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro | Q77874135 | ||
| Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent | Q79198459 | ||
| Ovarian cancer | Q84605146 | ||
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 | ||
| Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
| Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
| Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer | Q24650026 | ||
| Integrins: bidirectional, allosteric signaling machines | Q27860700 | ||
| Integrins in cancer: biological implications and therapeutic opportunities | Q29614536 | ||
| RGD and other recognition sequences for integrins | Q29616331 | ||
| Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin | Q30408322 | ||
| Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis | Q30430565 | ||
| Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics | Q30444706 | ||
| Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis | Q30447841 | ||
| The promise of antiangiogenic therapy for ovarian cancer | Q30449461 | ||
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial | Q33417361 | ||
| Recent advances in genetic modification of adenovirus vectors for cancer treatment | Q33738828 | ||
| Maximal cytoreductive effort in epithelial ovarian cancer surgery | Q33955721 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Ovarian cancer development and metastasis | Q34086819 | ||
| Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery | Q34198775 | ||
| Role of vascular endothelial growth factor in regulation of physiological angiogenesis | Q34249816 | ||
| A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) | Q34269566 | ||
| Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. | Q34311697 | ||
| Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. | Q34689304 | ||
| A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma | Q35212620 | ||
| A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer | Q35591666 | ||
| Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids | Q35747173 | ||
| Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin | Q35764323 | ||
| The regulation of integrin function by divalent cations | Q35998499 | ||
| Clinical significance of the integrin α6β4 in human malignancies. | Q36010634 | ||
| Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study | Q36087887 | ||
| The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin | Q36224126 | ||
| Elevated levels of Lewis y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma | Q36538265 | ||
| Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway | Q36592509 | ||
| VCAM1 expression correlated with tumorigenesis and poor prognosis in high grade serous ovarian cancer | Q36789013 | ||
| Expression of Lewis y antigen and integrin αv, β3 in ovarian cancer and their relationship with chemotherapeutic drug resistance | Q36976151 | ||
| Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target | Q37151287 | ||
| {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. | Q37413723 | ||
| Volociximab in cancer | Q37970775 | ||
| RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis | Q38042484 | ||
| Integrins and haptoglobin: Molecules overexpressed in ovarian cancer. | Q38820962 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins. | Q39109469 | ||
| A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer | Q39263789 | ||
| Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells | Q39527590 | ||
| Integrin-targeted paclitaxel nanoliposomes for tumor therapy | Q39678154 | ||
| Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. | Q40453891 | ||
| Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival | Q41671359 | ||
| The specifical inhibition of the expression of integrin alpha5/beta1 probably enhances the treatment effects and improves the prognosis of epithelial ovarian cancer | Q42177122 | ||
| A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma | Q42647126 | ||
| Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel | Q43287891 | ||
| AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients | Q44533910 | ||
| Incorporation of bevacizumab in the primary treatment of ovarian cancer | Q44579933 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P577 | publication date | 2017-07-08 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review | |
| P478 | volume | 9 |
| Q90523384 | Fluorescent Nanoparticles for the Guided Surgery of Ovarian Peritoneal Carcinomatosis |
| Q52651546 | High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors. |
| Q64992482 | Ligand-based pharmacophore model for the discovery of novel CXCR2 antagonists as anti-cancer metastatic agents. |
| Q64080771 | Nanocomposites as biomolecules delivery agents in nanomedicine |
| Q91935771 | PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3 |
| Q64252943 | Shedding New Light on The Role of ανβ3 and α5β1 Integrins in Rheumatoid Arthritis |
| Q48291586 | The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer |
| Q90107111 | The role of collagen in cancer: from bench to bedside |
| Q64062159 | Therapeutic Targeting of Collective Invasion in Ovarian Cancer |
| Q90633066 | Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression |
| Q47290265 | rLj-RGD3 Suppresses the Growth of HeyA8 Cells in Nude Mice |
Search more.